MaxCyte, Inc. (MXCT)
NASDAQ • Healthcare
Last close at September 10, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 11
in 62 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About MaxCyte, Inc.
MaxCyte, Inc. develops cell-engineering tools and cell therapeutics in biotechnology, selling electroporation instruments, related consumables, and supporting technology to drug developers. The company, listed on NASDAQ as MXCT, generated $33.0 million in FY2025 revenue from systems used in research, development, and therapeutic manufacturing.
Today's Snapshot
MXCT closed 2.5% lower at 1.19, in line with a weaker sector. Trading was lighter than usual, with volume about two-thirds of its usual level.
Trading Volume
Below 10d avg (477.0K)
300.4K
vs S&P 500 Today
Underperforming Market
-1.89%
Updated: September 10, 2026 at 20:32 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$1.18 - $1.26Sell
- RSI (14)42.86Neutral
- Stochastic %K (14, 3, 3)17.42Buy
- MACD Level (12, 26)0.00Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.